The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Atectura Breezhaler

125 micrograms /127.5 microgram(s) Inhalation powder, hard capsule

Novartis Europharm LimitedEU/1/20/1439/005-008

Main Information

Trade NameAtectura Breezhaler
Active SubstancesIndacaterol acetate
Mometasone furoate
Strength125 micrograms /127.5 microgram(s)
Dosage FormInhalation powder, hard capsule
Licence HolderNovartis Europharm Limited
Licence NumberEU/1/20/1439/005-008

Group Information

ATC CodeR03AK14 indacaterol and mometasone


Licence Issued30/05/2020
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back